Novavax shares are routed after its big PhIII RSV vaccine trial flops
Novavax $NVAX says that its big Phase III study of its RSV vaccine failed badly among older subjects, flopping on the primary as well as secondary outcomes and leaving the biotech struggling to explain how it fell short here.
The company recruited 11,856 people over the age of 60 for this study, looking for clear evidence to support a claim that the vaccine could significantly prevent RSV-associated lower respiratory tract disease – the primary goal – or at least incidents of all symptomatic respiratory disease due to RSV. It didn’t work.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
